Monika Rai

UK & European Patent Attorney

Monika is a life science specialist. Her practice focusses on advising on EP and UK patents in the field of diagnostics, biopharmaceuticals and biologics and she has significant experience of multi-party defensive and offensive oppositions at the EPO.  She has spent over a decade at top London private practice firms and has also gained valuable in-house experience. Monika is a Solicitor (England & Wales) as well a Patent Attorney and practiced in India prior to joining the UK patent profession.

Summary

Year joined: 2014

Qualifications: BSc LLB LLM EPA CPA

Expertise

Monika has substantial experience of contentious proceedings at the European Patent Office and has successfully represented clients at several opposition hearings. She has also coordinated and advised on major IP due diligence projects involving analysis of freedom to operate issues and contractual IP provisions. She advises a varied client base on patent prosecution and contentious matters in a range of technical areas, including diagnostic assays, therapeutic nucleotides and peptides, antibody formats, antibody discovery, stem cells, microbiome therapy products and inhaled small molecule formulations. This breadth of experience enables her to tailor her approach to suit client needs. Monika also contributes to training by being involved as an examiner on a Litigation Skills Course for newly qualified patent attorneys.

Academic

Monika has a first class bachelor of science in botany honours and a law degree, both from the University of Delhi. She then attended the London School of Economics and Political Science from where she gained a master of laws degree, specialising in intellectual property.

Membership & Organisations

Monika is a member of European Patent Institute and a fellow of The Chartered Institute of Patent Attorneys.

Specialisms

  • Patent Applications

  • Patent Drafting and Filing
  • Patent Enforcement
  • Patent Portfolio Management
  • Patent Oppositions
  • Litigation
  • IP Strategy
  • Commercialisation
  • Freedom to Operate
  • Due Diligence
  • Licensing



Follow us on twitter